Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
4 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to NewAmsterdam Pharma Company N.V.’s names, not what it holds today.
Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and 1 in 2023
Applications published
6
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
NewAmsterdam Pharma B.V. its own name
NL, as the owner printed on each patent
2 publishedNewAmsterdam Pharma B.V. its own name
named as the applicant on its applications, in NL
4 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 5, 2025 | 12,378,221 | Salts of obicetrapib and processes for their manufacture and intermediates thereof | Pharmaceuticals | NewAmsterdam Pharma B.V. |
| Jan 7, 2025 | 12,186,315 | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | Pharmaceuticals | NewAmsterdam Pharma B.V. |
| Jun 11, 2024 | 12,006,305 | Salts of obicetrapib and processes for their manufacture and intermediates thereof | Pharmaceuticals | NewAmsterdam Pharma B.V. |
| May 9, 2023 | 11,642,344 | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | Pharmaceuticals | NewAmsterdam Pharma B.V. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 25, 2025 | 2025/0296921 | Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof | Pharmaceuticals | NewAmsterdam Pharma B.V. |
| Jul 17, 2025 | 2025/0228852 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | Pharmaceuticals | NewAmsterdam Pharma B.V. |
| Jun 12, 2025 | 2025/0186442 | Obicetrapib and Ezetimibe Combination Treatment and Fixed Dose Pharmaceutical Compositions | Pharmaceuticals | NewAmsterdam Pharma B.V. |
| Nov 28, 2024 | 2024/0391897 | Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof | Pharmaceuticals | NewAmsterdam Pharma B.V. · patent 12,378,221 granted from it |
| Jun 13, 2024 | 2024/0189311 | Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia | Pharmaceuticals | NewAmsterdam Pharma B.V. |
| Jan 25, 2024 | 2024/0024315 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | Pharmaceuticals | NewAmsterdam Pharma B.V. · patent 12,186,315 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 6.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.